← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Vaxart, Inc. (VXRT) 10-Year Financial Performance & Capital Metrics

VXRT • • Industrial / General
HealthcareBiotechnologyInfectious DiseasesVaccine Development
AboutVaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.Show more
  • Revenue $29M +288.9%
  • EBITDA -$57M +23.1%
  • Net Income -$67M +18.8%
  • EPS (Diluted) -0.14 +17.6%
  • Gross Margin 100% +156.3%
  • EBITDA Margin -200.15% +80.2%
  • Operating Margin -230.99% +79.5%
  • Net Margin -233.27% +79.1%
  • ROE -114.71% -17.1%
  • ROIC -93.33% -7.2%
  • Debt/Equity 0.40 -13.9%
  • Interest Coverage -22.33 +61.2%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 95 (top 5%)
  • ✓Strong 5Y sales CAGR of 23.8%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.55%
5Y23.82%
3Y218.06%
TTM784.27%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM29.91%

EPS CAGR

10Y-
5Y-
3Y-
TTM-55.56%

ROCE

10Y Avg-66.84%
5Y Avg-61.51%
3Y Avg-76.79%
Latest-86.31%

Peer Comparison

Vaccine Development
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
DVAXDynavax Technologies Corporation1.78B15.6278.1019.36%-13.13%-8.13%3.39%0.43
VXRTVaxart, Inc.156.04M0.65-4.64288.94%-34.21%-189.5%0.40

Profit & Loss

Jun 2016Jun 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+9.3M8.9M5.84M4.16M9.86M4.05M892K107K7.38M28.7M
Revenue Growth %-0.62%-0.04%-0.34%-0.29%1.37%-0.59%-0.78%-0.88%67.96%2.89%
Cost of Goods Sold+100K17.63M12.36M17.27M019.86M48.75M04.5M0
COGS % of Revenue0.01%1.98%2.12%4.15%-4.91%54.65%-0.61%-
Gross Profit+9.2M-8.73M-6.52M-13.12M9.86M-15.82M-47.86M107K2.88M28.7M
Gross Margin %0.99%-0.98%-1.12%-3.15%1%-3.91%-53.65%1%0.39%1%
Gross Profit Growth %-0.56%-1.95%0.25%-1.01%1.75%-2.6%-2.03%1%25.91%8.97%
Operating Expenses+34.3M36.3M83K23.96M25.65M14.35M24.89M114.69M86.23M94.99M
OpEx % of Revenue3.69%4.08%0.01%5.76%2.6%3.55%27.91%1071.91%11.69%3.31%
Selling, General & Admin5.6M5.7M2.6M6.68M6.19M15.2M21.89M29.39M22.58M20.78M
SG&A % of Revenue0.6%0.64%0.45%1.61%0.63%3.76%24.54%274.64%3.06%0.72%
Research & Development26.3M28.3M12.36M17.27M14.54M19.86M48.75M81.05M68.14M74.21M
R&D % of Revenue2.83%3.18%2.12%4.15%1.47%4.91%54.65%757.51%9.23%2.59%
Other Operating Expenses100K200K004.92M-20.71M-45.74M4.25M-4.5M0
Operating Income+-25.2M-27.5M-9.12M-21.76M-15.79M-30.17M-72.75M-114.59M-83.35M-66.29M
Operating Margin %-2.71%-3.09%-1.56%-5.23%-1.6%-7.46%-81.56%-1070.91%-11.3%-2.31%
Operating Income Growth %-0.29%-0.09%0.67%-1.39%0.27%-0.91%-1.41%-0.58%0.27%0.2%
EBITDA+-25.1M-27.4M-8.73M-18.55M-12.19M-28.32M-70.32M-108.78M-74.72M-57.44M
EBITDA Margin %-2.7%-3.08%-1.5%-4.46%-1.24%-7%-78.83%-1016.65%-10.13%-2%
EBITDA Growth %-0.36%-0.09%0.68%-1.12%0.34%-1.32%-1.48%-0.55%0.31%0.23%
D&A (Non-Cash Add-back)100K100K380K3.2M3.6M1.85M2.43M5.8M8.62M8.85M
EBIT-25.1M-27.3M-9.12M-15.22M-15.77M-30.11M-68.88M-106.39M-80.76M-63.72M
Net Interest Income+-300K-1.8M0-2.62M-2.24M-1.8M-1.4M-58K1.21M-426K
Interest Income002.98M58K149K75K81K1.25M2.65M2.54M
Interest Expense300K1.8M02.68M2.39M1.87M1.48M1.3M1.45M2.97M
Other Income/Expense-200K-1.7M-467K3.86M-2.37M-1.81M2.39M6.9M1.14M-395K
Pretax Income+-25.4M-29.1M-9.58M-17.9M-18.16M-31.98M-70.36M-107.69M-82.2M-66.69M
Pretax Margin %-2.73%-3.27%-1.64%-4.3%-1.84%-7.9%-78.88%-1006.46%-11.14%-2.32%
Income Tax+0300K0109K490K238K107K67K261K260K
Effective Tax Rate %1%1.01%1.3%1.01%1.03%1.01%1%1%1%1%
Net Income+-25.4M-29.4M-12.46M-18.01M-18.64M-32.22M-70.47M-107.76M-82.47M-66.95M
Net Margin %-2.73%-3.3%-2.13%-4.33%-1.89%-7.96%-79%-1007.08%-11.18%-2.33%
Net Income Growth %-0.33%-0.16%0.58%-0.45%-0.04%-0.73%-1.19%-0.53%0.23%0.19%
Net Income (Continuing)-25.4M-29.4M-9.58M-18.01M-18.64M-32.22M-70.47M-107.76M-82.47M-66.95M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-0.72-0.84-0.28-0.29-0.09-0.07-0.14-0.22-0.17-0.14
EPS Growth %-0.22%-0.16%0.66%-0.01%0.7%0.23%-1.12%-0.57%0.23%0.18%
EPS (Basic)-0.72-0.84-0.33-0.29-0.09-0.07-0.14-0.22-0.17-0.14
Diluted Shares Outstanding35.12M35.13M44.07M63.16M215.7M487.26M487.26M487.26M487.26M487.26M
Basic Shares Outstanding35.12M35.13M37.84M63.16M215.7M487.26M487.26M487.26M487.26M487.26M
Dividend Payout Ratio----------

Balance Sheet

Jun 2016Jun 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+72.4M39.9M3.75M14.64M17.6M128.53M169.17M99.45M45.54M68.26M
Cash & Short-Term Investments69M38.6M2.99M11.46M13.53M126.87M166.49M93.72M39.71M51.72M
Cash Only49.7M17.7M1.57M11.46M13.53M126.87M143.75M44.01M34.76M25.23M
Short-Term Investments19.3M20.9M1.42M00022.74M49.7M4.96M26.49M
Accounts Receivable700K600K630K1.8M3.62M334K71K20K3.01M11.97M
Days Sales Outstanding27.4724.6139.38157.62133.9430.1329.0568.22148.79152.22
Inventory0000000000
Days Inventory Outstanding----------
Other Current Assets2.7M001.34M01.33M02M333K318K
Total Non-Current Assets+300K200K770K20.58M19.43M24.05M52M54.4M46.29M98.13M
Property, Plant & Equipment300K200K730K1.07M2.2M8.32M19.77M41.3M36.57M29.11M
Fixed Asset Turnover31.00x44.50x8.00x3.90x4.48x0.49x0.05x0.00x0.20x0.99x
Goodwill0000004.51M4.51M4.51M4.51M
Intangible Assets48K44K40K19.41M17.09M15.36M10.62M5.02M4.29M3.56M
Long-Term Investments00000016.21M000
Other Non-Current Assets-48K-44K0103K141K372K890K3.57M926K60.95M
Total Assets+72.7M40.1M4.52M35.23M37.03M152.58M221.17M153.85M91.83M166.39M
Asset Turnover0.13x0.22x1.29x0.12x0.27x0.03x0.00x0.00x0.08x0.17x
Asset Growth %-0.08%-0.45%-0.89%6.79%0.05%3.12%0.45%-0.3%-0.4%0.81%
Total Current Liabilities+9.2M5.9M4.52M7.47M9.17M11.76M10.78M17.92M13.72M90.88M
Accounts Payable3.9M1.4M1.39M962K852K2.13M3.87M5.51M1.58M6.96M
Days Payables Outstanding14.23K28.9841.0620.33-39.228.99-128.48-
Short-Term Debt400K200K1.53M1.67M04.83M836K95K3.8M4.06M
Deferred Revenue (Current)1000K1000K01000K1000K00000
Other Current Liabilities4.3M3.9M88K3.78M2.01M3.18M12M065.4M
Current Ratio7.87x6.76x0.83x1.96x1.92x10.93x15.69x5.55x3.32x0.75x
Quick Ratio7.87x6.76x0.83x1.96x1.92x10.93x15.69x5.55x3.32x0.75x
Cash Conversion Cycle----------
Total Non-Current Liabilities+17.3M15.5M38.72M16.51M14.91M17.41M22.85M25.33M20.3M16.59M
Long-Term Debt300K100K38.72M1.94M012.15M10.69M5.62M2.62M1.7M
Capital Lease Obligations00001.47M5.16M12M19.48M17.39M14.45M
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities17M15.4M014.57M13.43M109K171K231K293K439K
Total Liabilities26.5M21.4M43.24M23.99M24.08M29.18M33.64M43.25M34.02M107.46M
Total Debt+700K300K40.25M3.61M2.31M22.14M24.53M27.42M26.51M23.28M
Net Debt-49M-17.4M38.68M-7.84M-11.21M-104.73M-119.22M-16.59M-8.24M-1.95M
Debt / Equity0.02x0.02x-0.32x0.18x0.18x0.13x0.25x0.46x0.40x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-84.00x-15.28x--8.12x-6.61x-16.10x-49.16x-87.81x-57.60x-22.33x
Total Equity+46.2M18.7M-38.72M11.24M12.95M123.4M187.53M110.6M57.8M58.92M
Equity Growth %-0.34%-0.6%-3.07%1.29%0.15%8.53%0.52%-0.41%-0.48%0.02%
Book Value per Share1.320.53-0.880.180.060.250.380.230.120.12
Total Shareholders' Equity46.2M18.7M-38.72M11.24M12.95M123.4M187.53M110.6M57.8M58.92M
Common Stock3.9M3.9M0714K5K11K13K13K15K23K
Retained Earnings-134.3M-163.8M-79.98M-97.99M-116.66M-148.88M-219.35M-327.11M-409.57M-476.52M
Treasury Stock00000000-366K-350K
Accumulated OCI19M19M0000-74K-299K-1K4K
Minority Interest0000000000

Cash Flow

Jun 2016Jun 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-14.1M-30M-10.04M-14.55M-13.09M-23.75M-59.83M-94.78M-70.45M-44.76M
Operating CF Margin %-1.52%-3.37%-1.72%-3.5%-1.33%-5.87%-67.08%-885.79%-9.55%-1.56%
Operating CF Growth %-0.47%-1.13%0.67%-0.45%0.1%-0.81%-1.52%-0.58%0.26%0.36%
Net Income-25.4M-29.4M-9.58M-18.01M-18.64M-32.22M-70.47M-107.76M-82.47M-66.95M
Depreciation & Amortization100K100K380K3.2M3.6M2.71M4.21M5.8M8.62M8.85M
Stock-Based Compensation2M1.9M477K539K627K4.36M8.87M13.59M14.13M11.5M
Deferred Taxes0001.72M1.37M03.09M4.09M00
Other Non-Cash Items100K-1.4M-2.25M-4.45M-1.32M-1.4M-3.41M-5.81M106K-1.43M
Working Capital Changes9.1M-1.2M935K2.45M1.28M2.81M-2.12M-4.7M-10.85M3.26M
Change in Receivables11.9M100K960K13.5M-1.82M3.29M263K51K-2.99M-2.75M
Change in Inventory0000000-7.11M00
Change in Payables-700K-3.3M0-3.78M-62K1.21M1.63M357K-2.44M5.27M
Cash from Investing+1.3M-1.6M3.18M26.21M-850K-1.22M-49.1M-20.41M43.95M-21.32M
Capital Expenditures-200K-530K-117K-707K-850K-1.22M-5.16M-9.6M-1.87M-554K
CapEx % of Revenue0.02%0.06%0.02%0.17%0.09%0.3%5.78%89.73%0.25%0.02%
Acquisitions----------
Investments----------
Other Investing-259K-2.2M3.3M1.42M000-10.81M0-9.95M
Cash from Financing+17.8M-400K24K-1.73M15.96M138.31M125.8M17.46M15.24M56.56M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing18.1M024K13K1.41M27.2M3.59M225K213K-214K
Net Change in Cash----------
Free Cash Flow+-14.3M-30.53M-10.16M-15.26M-13.94M-24.97M-64.99M-104.38M-72.32M-45.32M
FCF Margin %-1.54%-3.43%-1.74%-3.67%-1.41%-6.17%-72.86%-975.51%-9.8%-1.58%
FCF Growth %-0.47%-1.13%0.67%-0.5%0.09%-0.79%-1.6%-0.61%0.31%0.37%
FCF per Share-0.41-0.87-0.23-0.24-0.06-0.05-0.13-0.21-0.15-0.09
FCF Conversion (FCF/Net Income)0.56x1.02x0.81x0.81x0.70x0.74x0.85x0.88x0.85x0.67x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-43.91%-90.6%--160.23%-154.15%-47.26%-45.33%-72.29%-97.94%-114.71%
Return on Invested Capital (ROIC)-164.35%-1586.54%-1087.71%-974.15%-461.37%-221.73%-125.45%-105.89%-87.08%-93.33%
Gross Margin98.92%-98.13%-111.59%-315.36%100%-390.93%-5365.13%100%39.02%100%
Net Margin-273.12%-330.34%-213.39%-432.96%-189.06%-796.34%-7900.22%-100708.41%-1117.56%-233.27%
Debt / Equity0.02x0.02x-0.32x0.18x0.18x0.13x0.25x0.46x0.40x
Interest Coverage-84.00x-15.28x--8.12x-6.61x-16.10x-49.16x-87.81x-57.60x-22.33x
FCF Conversion0.56x1.02x0.81x0.81x0.70x0.74x0.85x0.88x0.85x0.67x
Revenue Growth-62.2%-4.3%-34.39%-28.77%137.12%-58.97%-77.95%-88%6796.26%288.94%

Revenue by Segment

2018201920202021202220232024
Government Contract1.34M-20K----65.4M
Government Contract Growth--101.49%-----
Non Cash Royalty Revenue1.48M---107K3.92M3.84M
Non Cash Royalty Revenue Growth-----3563.55%-1.99%
Grant-----3.46M-
Grant Growth-------
Customer Service Contracts--198K----
Customer Service Contracts Growth-------

Frequently Asked Questions

Growth & Financials

Vaxart, Inc. (VXRT) reported $148.2M in revenue for fiscal year 2024. This represents a 899% increase from $14.8M in 2011.

Vaxart, Inc. (VXRT) grew revenue by 288.9% over the past year. This is strong growth.

Vaxart, Inc. (VXRT) reported a net loss of $50.7M for fiscal year 2024.

Dividend & Returns

Vaxart, Inc. (VXRT) has a return on equity (ROE) of -114.7%. Negative ROE indicates the company is unprofitable.

Vaxart, Inc. (VXRT) had negative free cash flow of $30.5M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.